11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients

• Published in: Current radiopharmaceuticals Vol. 10; no. 3; p. 195
• Main Authors: Incerti, Elena, Gangemi, Vincenzo, Mapelli, Paola, Deantoni, Chiara Lucrezia, Giovacchini, Giampiero, Fallanca, Federico, Fodor, Andrei, Ciarmiello, Andrea, Baldari, Sergio, Gianolli, Luigi, Di Muzio, Nadia, Picchio, Maria
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 10.11.2017
• Subjects: helical tomotherapy; 11C-choline PET/CT; prostate cancer; biochemical response; Bone metastases; survival
• ISSN: 1874-4729
• DOI: 10.2174/1874471010666170919162517

To evaluate the efficacy of 11C-choline PET/CT (CHO-PET/CT) based helical tomotherapy (HTT) as a therapeutic approach for bone metastases in recurrent prostate cancer (PCa) patients. This retrospective study includes 20 PCa patients (median age: 67; range: 51-80 years) presenting biochemical relapse after primary treatment who underwent CHO-PET/CT based HTT on positive bone metastases from December 2007 to June 2014. The effectiveness of HTT has been assessed with biochemical response at 3/6/12 months, biochemical relapse free survival (bRFS) and overall survival (OS) at 2 years. Toxicity has also been considered and assessed according to Common Terminology Criteria for Adverse Events (CTCAE). All patients presented a relapse at the time of CHO-PET/CT at bone level. In addition 15/20 (75%) also at lymph nodes (LNs) level (total lesions= 54). All patients underwent HTT on bone metastases and 19/20 concomitantly on prostatic bed and LNs. The median follow-up from CHO-PET/CT was 2 years (range: 1-7 years). At 3 months after the beginning of HTT treatment complete or partial biochemical response occurred in 79% of patients, at 6 months in 82% and at 12 months in 63% of patients. bRFS and OS at 2 years were 50% and 55% of patients, respectively. Patients presented mostly grade 1 or 2 toxicity according to CTCAE. The only grade 3 late toxicity has been observed in one patient. CHO-PET/CT based HTT is a suitable therapeutic approach in patients with recurrent PCa presenting bone metastases with a medium-low toxicity.